Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: PNL013
MIFTS: 33

Penile Disease

Categories: Reproductive diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Penile Disease

About this section

MalaCards integrated aliases for Penile Disease:

Name: Penile Disease 12 15
Penile Diseases 73

Classifications:

MalaCards categories:
Anatomical: Reproductive diseases
See all MalaCards categories (disease lists)
ICD10: 33


External Ids:

Disease Ontology 12 DOID:1529
ICD10 33 N48.8 N48.89
ICD9CM 35 607.8 607.89
Sources

Summaries for Penile Disease

About this section
MalaCards based summary : Penile Disease, also known as penile diseases, is related to mental retardation, truncal obesity, retinal dystrophy, and micropenis syndrome and conjunctival intraepithelial neoplasm, and has symptoms including pelvic pain An important gene associated with Penile Disease is PDE5A (Phosphodiesterase 5A), and among its related pathways/superpathways are Response to elevated platelet cytosolic Ca2+ and Pathways in cancer. The drugs mometasone furoate and Ropivacaine have been mentioned in the context of this disorder. Affiliated tissues include skin, prostate and tongue, and related phenotypes are hematopoietic system and immune system

Wikipedia : 76 The human penis is an external male intromittent organ that additionally serves as the urinal duct. The... more...

Sources

Related Diseases for Penile Disease

About this section

Diseases related to Penile Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 49)
# Related Disease Score Top Affiliating Genes
1 mental retardation, truncal obesity, retinal dystrophy, and micropenis syndrome 11.2
2 conjunctival intraepithelial neoplasm 10.3 CDKN2A IFNA2
3 giant hemangioma 10.2 IFNA2 TGFB1
4 spinocerebellar ataxia, autosomal recessive 10 10.2 IFNA2 SCN10A
5 bladder squamous cell carcinoma 10.2 CDKN2A TP53
6 conjunctival squamous cell carcinoma 10.2 IFNA2 TP53
7 keratinizing squamous cell carcinoma 10.2 CDKN2A TP53
8 spitz nevus 10.2 CDKN2A TP53
9 orbital plasma cell granuloma 10.2 IFNA2 MRAP
10 bladder carcinoma in situ 10.2 CDKN2A TP53
11 vulva squamous cell carcinoma 10.2 CDKN2A TP53
12 scrotal carcinoma 10.2 CDKN2A TP53
13 nasal cavity adenocarcinoma 10.2 CDKN2A TP53
14 bartholin's gland disease 10.2 CDKN2A TP53
15 peyronie disease 10.2 IFNA2 PDE5A TGFB1
16 anal squamous cell carcinoma 10.2 CDKN2A TP53
17 megaesophagus 10.2 CDKN2A TP53
18 glycogen-rich clear cell breast carcinoma 10.2 CDKN2A TP53
19 vulvar dystrophy 10.2 CDKN2A LINC01191
20 gastric adenosquamous carcinoma 10.1 CDKN2A TP53
21 cervical carcinosarcoma 10.1 GP6 TP53
22 discitis 10.1 MID2 MRAP
23 vulval paget's disease 10.1 CDKN2A LINC01191
24 balanoposthitis 10.1 CDKN2A GP6
25 oral leukoplakia 10.1 CDKN2A TP53
26 vasculogenic impotence 10.1 NOS3 PDE5A
27 vulva adenocarcinoma 10.1 CDKN2A LINC01191
28 chronic orbital inflammation 10.1 IFNA2 MRAP
29 transitional cell carcinoma 10.1 CDKN2A IFNA2 TP53
30 recessive dystrophic epidermolysis bullosa 10.1 CDKN2A TGFB1 TP53
31 focal epithelial hyperplasia 10.1 GP6 IFNA2 TP53
32 cervix uteri carcinoma in situ 10.1 CDKN2A GP6 TP53
33 uterus carcinoma in situ 10.1 CDKN2A GP6 TP53
34 cervicitis 10.1 CDKN2A MRAP
35 cervix disease 10.1 CDKN2A GP6 TP53
36 uterine anomalies 10.1 CDKN2A GP6 TP53
37 meningeal melanomatosis 10.1 CDKN2A TP53
38 breast disease 10.0 CDKN2A TGFB1 TP53
39 melanoma, cutaneous malignant 1 10.0 CDKN2A IFNA2 TP53
40 suppressor of tumorigenicity 3 10.0 CDKN2A TP53
41 vulvar disease 9.9 CDKN2A LINC01191 SCN10A TP53
42 vulva cancer 9.9 CDKN2A LINC01191 SCN10A TP53
43 anus disease 9.9 CDKN2A LINC01191 MID2 TLR7
44 rectal disease 9.9 CDKN2A LINC01191 MID2 TLR7
45 vulvitis 9.9 LINC01191 MRAP
46 anogenital venereal wart 9.8 CDKN2A GP6 MID2 TLR7 TP53
47 penile cancer 9.8 CDKN2A FAM92A IFNA2 SCN10A TP53
48 herpangina 9.8 GP6 IFNA2 LINC01191 MID2 TLR7
49 impotence 9.7

Comorbidity relations with Penile Disease via Phenotypic Disease Network (PDN):


Prostatic Hypertrophy

Graphical network of the top 20 diseases related to Penile Disease:



Diseases related to Penile Disease
Sources

Symptoms & Phenotypes for Penile Disease

About this section

UMLS symptoms related to Penile Disease:


pelvic pain

MGI Mouse Phenotypes related to Penile Disease:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.81 CDKN2A FAM92A GP6 IPP NOS3 SMAD2
2 immune system MP:0005387 9.61 CDKN2A FAM92A GP6 IPP NOS3 SMAD2
3 respiratory system MP:0005388 9.1 CDKN2A NOS3 SCN10A SMAD2 TGFB1 TP53
Sources

Drugs & Therapeutics for Penile Disease

About this section

Drugs for Penile Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 216)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
mometasone furoate Approved, Vet_approved Phase 4 83919-23-7
2
Ropivacaine Approved Phase 4,Not Applicable 84057-95-4 175805 71273
3
Dexmedetomidine Approved, Vet_approved Phase 4,Phase 3 113775-47-6 68602 5311068
4
Bupivacaine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 2180-92-9, 38396-39-3 2474
5 Anti-Inflammatory Agents Phase 4,Phase 1,Not Applicable
6 Anti-Allergic Agents Phase 4
7 Dermatologic Agents Phase 4,Phase 2
8 Adrenergic Agonists Phase 4,Phase 2,Phase 3,Not Applicable
9 Adrenergic alpha-Agonists Phase 4,Phase 2,Phase 3,Not Applicable
10 Neurotransmitter Agents Phase 4,Phase 2,Phase 3,Not Applicable
11 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
12 Adrenergic Agents Phase 4,Phase 2,Phase 3,Not Applicable
13 Anti-Asthmatic Agents Phase 4,Phase 2,Phase 3,Not Applicable
14 Respiratory System Agents Phase 4,Phase 2,Phase 3,Not Applicable
15 Anesthetics Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
16 Central Nervous System Depressants Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
17 Analgesics Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
18 Analgesics, Non-Narcotic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
19 Anesthetics, Local Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
20 Hypnotics and Sedatives Phase 4,Phase 3,Phase 2
21 Adrenergic alpha-2 Receptor Agonists Phase 4,Phase 3,Phase 2
22 Hormone Antagonists Phase 4,Phase 3,Phase 1,Not Applicable,Early Phase 1
23 glucocorticoids Phase 4,Not Applicable
24 Hormones Phase 4,Phase 3,Phase 1,Not Applicable,Early Phase 1
25 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 1,Not Applicable,Early Phase 1
26
Epinephrine Approved, Vet_approved Phase 2, Phase 3,Not Applicable 51-43-4 5816
27
Racepinephrine Approved Phase 2, Phase 3,Not Applicable 329-65-7 838
28
Atracurium Approved, Experimental, Investigational Phase 2, Phase 3 64228-79-1 47319
29
Thiopental Approved, Vet_approved Phase 2, Phase 3 76-75-5 3000715
30
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 2, Phase 3,Phase 3 437-38-7 3345
31
Neostigmine Approved, Vet_approved Phase 2, Phase 3 59-99-4 4456
32
Atropine Approved, Vet_approved Phase 2, Phase 3 51-55-8, 5908-99-6 174174
33
Nitrous oxide Approved, Vet_approved Phase 2, Phase 3,Not Applicable 10024-97-2 948
34
Isoflurane Approved, Vet_approved Phase 2, Phase 3 26675-46-7 3763
35
Estradiol Approved, Investigational, Vet_approved Phase 3 50-28-2 5757
36
Testosterone Approved, Investigational Phase 3,Phase 1,Early Phase 1 58-22-0 6013
37 Estradiol valerate Approved, Investigational, Vet_approved Phase 3 979-32-8
38
Polyestradiol phosphate Approved Phase 3 28014-46-2
39 Adrenergic beta-Agonists Phase 2, Phase 3,Not Applicable
40 Vasoconstrictor Agents Phase 2, Phase 3,Not Applicable
41 Epinephryl borate Phase 2, Phase 3,Not Applicable
42 Cholinergic Agents Phase 2, Phase 3
43 Mydriatics Phase 2, Phase 3,Not Applicable
44 Pharmaceutical Solutions Phase 2, Phase 3
45 Sympathomimetics Phase 2, Phase 3,Not Applicable
46 Autonomic Agents Phase 2, Phase 3,Not Applicable
47 Bronchodilator Agents Phase 2, Phase 3,Not Applicable
48 Anti-Arrhythmia Agents Phase 2, Phase 3
49 Adjuvants, Anesthesia Phase 2, Phase 3,Phase 3
50 Muscarinic Antagonists Phase 2, Phase 3

Interventional clinical trials:

(show top 50) (show all 109)
# Name Status NCT ID Phase Drugs
1 Treatment of Phimosis With Topical Steroid Cream -Double-blind, Randomized, Placebo-controlled Study Unknown status NCT01108198 Phase 4 Mometasone furoate cream;moisturizing cream
2 Pudendal Block Versus Caudal Block for Hypospadias Completed NCT02390388 Phase 4
3 Effects of Dexmedetomidine as Adjunct to Pudendal Block for Pediatric Penile Surgery Completed NCT02848157 Phase 4 Dexmedetomidine;plain ropivacaine;Ropivacaine
4 Xiaflex® Plus Testosterone Treatment Pilot Study Protocol Recruiting NCT03815331 Phase 4 Xiaflex®;Aveed
5 Treatment Response to Xiaflex for Men With Peyronie's Disease Recruiting NCT03774264 Phase 4 Xiaflex
6 Effect of Intravenous Paracetamol in Combination With Caudal Ropivacaine on Quality of Postoperative Recovery in Paediatric Patients Undergoing Hypospadias Repair Recruiting NCT03781505 Phase 4 Paracetamol +caudal ropivacaine
7 Does Caudal Block Increase the Incidence of Urethrocutaneous Fistula Formation Following Hypospadias Repair in Infants? Recruiting NCT02861950 Phase 4 Caudal block with ropivacaine;penile nerve block with bupivacaine
8 Additional Xiaflex® Treatment in Patients With Peyronie's Disease Recurrence, Worsening, or Incomplete Response Recruiting NCT03767452 Phase 4 Xiaflex® 0.58 mg
9 Mild Versus Potent Corticosteroids as Treatment for Phimosis in Children Withdrawn NCT00933023 Phase 4 hydrocortisone;Betamethasone
10 An Open-label Study to Assess the Safety and Effectiveness of AA4500 in Combination With the ErecAid® Esteem® Manual Vacuum Therapy System in Treating Men With Peyronie's Disease Completed NCT02267460 Phase 3
11 A Phase 3, Open-label Study of the Safety and Effectiveness of AA4500 Administered Twice Per Treatment Cycle for up to Four Treatment Cycles (2 x 4) in Men With Peyronie's Disease Completed NCT01685437 Phase 3
12 A Study of AA4500 in Men With Peyronie's Disease Completed NCT01243411 Phase 3
13 Study of AA4500 in the Treatment of Peyronie's Disease Completed NCT01221623 Phase 3
14 Study of AA4500 in the Treatment of Peyronie's Disease Completed NCT01221597 Phase 3
15 Effectiveness of Caudal Epidural Block on Intraoperative Blood Loss During Hypospadias Repair Completed NCT02752308 Phase 2, Phase 3 Bupivacaine;Dilute epinephrine injection;Fentanyl;dextrose plus sodium chloride.;neostigmine and atropine
16 Dexmedetomidine Infusion in Hypospadias Surgery Completed NCT00926705 Phase 3 Dexmedetomidine and Fentanyl;Fentanyl
17 Local Oestrogen Versus Placebo as Preoperative Treatment in Patients With Severe Hypospadias: Effects on Post-operative Complications Completed NCT01370798 Phase 3 promestriene;Placebo
18 H-22411: BOTOX® for Peyronie's Disease Unknown status NCT00812838 Phase 2 100 units of Botulinum Toxin Type A
19 Phase II Study of Dietary Cholesterol for Smith-Lemli-Opitz Syndrome Unknown status NCT00004347 Phase 2
20 Pharmacokinetics of a Single Treatment Cycle of AA4500 0.58 mg in Men With Peyronie's Disease Completed NCT01430169 Phase 2
21 The Safety and Effectiveness of AA4500 in Subjects With Peyronie's Disease Completed NCT00755222 Phase 2
22 A Trial of Cabazitaxel Chemotherapy in Relapsed Locally Advanced &/or Metastatic Carcinoma of the Penis Completed NCT03114254 Phase 2 Cabazitaxel
23 Irinotecan and Cisplatin in Treating Patients With Locally Advanced or Metastatic Penile Cancer Completed NCT00066391 Phase 2 cisplatin;irinotecan hydrochloride
24 Association of Different Doses of Clonidine in Caudal Epidural Anesthesia for Hypospadias Surgery Completed NCT02769390 Phase 2 Clonidine 1 mcg/Kg;Clonidine 2 mcg/ Kg;Clonidine 3 mcg/ Kg
25 T Cell Receptor Immunotherapy Targeting HPV-16 E6 for HPV-Associated Cancers Completed NCT02280811 Phase 1, Phase 2 Fludarabine;Cyclophosphamide;Aldesleukin
26 Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Human Papillomavirus-Associated Cancers Completed NCT01585428 Phase 2 Fludarabine;Cyclophosphamide;Aldesleukin
27 Vaccine Therapy in Preventing Human Papillomavirus Infection in Young HIV-Positive Male Patients Who Have Sex With Males Completed NCT01209325 Phase 2
28 Sildenafil for Treatment of Priapism in Men With Sickle Cell Anemia Completed NCT00940901 Phase 2 sildenafil
29 Neoadjuvant Chemotherapy for Patients With Squamous Cell Carcinoma of the Penis Completed NCT00512096 Phase 2 Ifosfamide;Paclitaxel (Taxol);Cisplatin
30 Treatment of the Cholesterol Defect in Smith-Lemli-Opitz Syndrome Completed NCT00272844 Phase 1, Phase 2 crystalline cholesterol oil-based suspension
31 Short-term Behavioral Effects of Cholesterol Therapy in Smith-Lemli-Opitz Syndrome Completed NCT00114634 Phase 2
32 Isotretinoin Plus Interferon in Treating Patients With Recurrent Cancer Completed NCT00002506 Phase 2 isotretinoin
33 Simvastatin Therapy in Smith-Lemli-Opitz Syndrome Completed NCT00064792 Phase 2 Simvastatin Susp.;OraPlus
34 PEnile Cancer Radio- and Immunotherapy CLinical Exploration Study Recruiting NCT03686332 Phase 2 Arm A: Atezolizumab and Radiotherapy;Arm B: Atezolizumab
35 DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Participants With Recurrent or Metastatic Human Papillomavirus Associated Cancers Recruiting NCT03439085 Phase 2
36 M7824 in Subjects With HPV Associated Malignancies Recruiting NCT03427411 Phase 2 M7824
37 HPV Anti-CD40 RNA Vaccine Recruiting NCT03418480 Phase 1, Phase 2 HPV vaccine
38 A Study of Avelumab in Penile Cancer Who Are Unfit for or Have Progressed After Platinum-Based Chemotherapy Recruiting NCT03391479 Phase 2 Avelumab
39 Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors Recruiting NCT03333616 Phase 2 Ipilimumab;Nivolumab
40 Secured Access to Nivolumab for Adult Patients With Selected Rare Cancer Types Recruiting NCT03012581 Phase 2 Nivolumab
41 Evaluation of Lymphadenectomy and Chemotherapy TIP on Inguinal Lymph Nodes in Squamous Cell Carcinoma of the Penis (AFU-GETUG 25) Recruiting NCT02817958 Phase 2 Chemotherapie TIP
42 Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic Recruiting NCT02721732 Phase 2
43 Cholesterol and Antioxidant Treatment in Patients With Smith-Lemli-Opitz Syndrome (SLOS) Recruiting NCT01773278 Phase 2 Antioxidants;Cholesterol
44 Dacomitinib (PF-00299804) in Advanced/Metastatic Squamous Cell Carcinoma of the Penis Recruiting NCT01728233 Phase 2 Dacomitinib
45 A Phase II Trial of Vinflunine Chemotherapy in Locally-advanced and Metastatic Carcinoma of the Penis (VinCaP) Active, not recruiting NCT02057913 Phase 2 Vinflunine
46 Maintenance Avelumab Immunotherapy in Patients With Locally Advanced or Metastatic Squamous Cell Penile Carcinoma Not yet recruiting NCT03774901 Phase 2 Avelumab
47 Smith-Lemli-Opitz Syndrome and Cholic Acid Not yet recruiting NCT03720990 Phase 1, Phase 2 Cholic Acid
48 S0224, Docetaxel in Treating Patients With Locally Advanced or Metastatic Penile Cancer (TERMINATED) Terminated NCT00058448 Phase 2 docetaxel
49 Efficacy and Safety of Cetuximab in Metastatic Penile Carcinoma (PENILANE) Withdrawn NCT02014831 Phase 2 Cetuximab;TIP
50 Tadalafil for Treatment of Priapism in Men With Sickle Cell Anemia Withdrawn NCT00538564 Phase 2 tadalafil;placebo

Search NIH Clinical Center for Penile Disease

Sources

Genetic Tests for Penile Disease

About this section
Sources

Anatomical Context for Penile Disease

About this section

MalaCards organs/tissues related to Penile Disease:

41
Skin, Prostate, Tongue, Tonsil, Cervix, Thyroid, Uterus
Sources

Publications for Penile Disease

About this section

Articles related to Penile Disease:

# Title Authors Year
1
MR imaging of scrotal, testicular, and penile diseases. ( 8873019 )
1996
2
Vascular impotence: focal or diffuse penile disease. ( 1433544 )
1992
Sources

Variations for Penile Disease

About this section
Sources

Expression for Penile Disease

About this section
Search GEO for disease gene expression data for Penile Disease.
Sources

Pathways for Penile Disease

About this section

Pathways related to Penile Disease according to GeneCards Suite gene sharing:

(show all 19)
# Super pathways Score Top Affiliating Genes
1
Response to elevated platelet cytosolic Ca2+ 66
Show member pathways
 13.08 GP6 IFNA2 NOS3 PDE5A TGFB1 TP53
2
Pathways in cancer 37
12.52 CDKN2A IFNA2 SMAD2 TGFB1 TP53
3
Human T-cell leukemia virus 1 infection 37
12.16 CDKN2A SMAD2 TGFB1 TP53
4
Cell cycle 1 37
12.03 CDKN2A SMAD2 TGFB1 TP53
5
TGF-beta Signaling Pathway (WikiPathways) 1
11.87 SMAD2 TGFB1 TP53
6
Th1 Differentiation Pathway 65
Show member pathways
 11.85 SMAD2 TGFB1 TLR7
7
DNA Damage Response (only ATM dependent) 1
11.77 CDKN2A TGFB1 TP53
8
Senescence and Autophagy in Cancer 1
11.71 CDKN2A TGFB1 TP53
9
AGE-RAGE signaling pathway in diabetic complications 37
11.65 NOS3 SMAD2 TGFB1
10
SMAD Signaling Network 64
11.64 CDKN2A SMAD2 TGFB1 TP53
11
Dendritic Cells Developmental Lineage Pathway 65
11.48 IFNA2 TGFB1 TLR7
12
Colorectal Cancer Metastasis 64
11.47 SMAD2 TGFB1 TLR7 TP53
13
HIF1Alpha Pathway 64
11.23 CDKN2A NOS3 TP53
14
Transcription_P53 signaling pathway 22
11.19 CDKN2A SMAD2 TGFB1 TP53
15
Cellular senescence (KEGG) 37
11.13 CDKN2A SMAD2 TGFB1 TP53
16
Inhibition of Ribosome Biogenesis by p14(ARF) 64
10.93 CDKN2A TP53
17
TP53 Network 1
Show member pathways
 10.92 CDKN2A TP53
18
TGF-B Signaling in Thyroid Cells for Epithelial-Mesenchymal Transition 1
10.8 SMAD2 TGFB1
19
NO-dependent CFTR activation (normal and CF) 22
10.61 NOS3 PDE5A
Sources

GO Terms for Penile Disease

About this section

Biological processes related to Penile Disease according to GeneCards Suite gene sharing:

(show all 17)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription, DNA-templated GO:0045893 9.88 CDKN2A IFNA2 SMAD2 TGFB1 TP53
2 negative regulation of transcription, DNA-templated GO:0045892 9.83 CDKN2A IFNA2 SMAD2 TGFB1 TP53
3 cell cycle arrest GO:0007050 9.73 CDKN2A TGFB1 TP53
4 negative regulation of cell growth GO:0030308 9.69 CDKN2A TGFB1 TP53
5 regulation of transforming growth factor beta receptor signaling pathway GO:0017015 9.57 SMAD2 TGFB1
6 negative regulation of viral entry into host cell GO:0046597 9.55 IFNA2 MID2
7 negative regulation of cell proliferation GO:0008285 9.55 CDKN2A NOS3 SMAD2 TGFB1 TP53
8 regulation of sodium ion transport GO:0002028 9.54 NOS3 TGFB1
9 negative regulation of protein localization to plasma membrane GO:1903077 9.52 MRAP TGFB1
10 replicative senescence GO:0090399 9.49 CDKN2A TP53
11 response to cholesterol GO:0070723 9.46 SMAD2 TGFB1
12 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.4 TGFB1 TP53
13 negative regulation of biomineral tissue development GO:0070168 9.37 NOS3 TGFB1
14 positive regulation of gene expression GO:0010628 9.35 CDKN2A NOS3 SMAD2 TGFB1 TP53
15 SMAD protein complex assembly GO:0007183 9.32 SMAD2 TGFB1
16 common-partner SMAD protein phosphorylation GO:0007182 9.26 SMAD2 TGFB1
17 regulation of binding GO:0051098 8.62 SMAD2 TGFB1

Molecular functions related to Penile Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 type I transforming growth factor beta receptor binding GO:0034713 8.96 SMAD2 TGFB1
2 disordered domain specific binding GO:0097718 8.8 CDKN2A SMAD2 TP53
Sources

Sources for Penile Disease

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....